Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Expects 11 Percent Drop in 2019 Revenues

NEW YORK — HTG Molecular Diagnostics said Monday that it expects to report a nearly 11 percent year-over-year drop in revenues for 2019.

According to the Tuscon, Arizona-based company, total revenues for 2019 are expected to be $19.2 million compared with $21.5 million in 2018. On average, analysts are expecting HTG to report 2019 revenues of approximaltely $19.4 million.

HTG also said that it expects its cash and cash equivalents to total $33.0 million at the end of 2019, with an additional $3.3 million of restricted cash held in connection with a convertible note that will be included in its current liabilities.

"Our performance for 2019 reflects both the continued growth of our [research-use only] profiling business and the impact of lower collaborative development services program activities," HTG CEO John Lubniewski said in a statement. "We are optimistic about the continuing opportunities in profiling and collaborative development services and look forward to building a proprietary molecular diagnostic with an initial, strategic focus on breast cancer diagnostic testing."

HTG, which recently filed for a $20 million stock offering after being warned that its stock was not in compliance with the Nasdaq's $1 minimum closing bid price, plans to announce full financial results for 2019 in March.

During early morning trading, shares of HTG fell more than 5 percent to $.75.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.